About
Therapies based on the function of NGLY1, AAV gene therapy, small molecules
Areas of Focus
Categories
Virus TechnologySmall Molecule PharmaceuticalGene Therapy, RNA & Peptide TherapyBiotech
Team (8)
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
76
By Phase
NA: 2PHASE1/PHASE2: 1
By Status
ENROLLING_BY_INVITATION: 1COMPLETED: 1RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07052721Collaborator
Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery
NAEnrolling by invitation
50 participants
Started: Sep 5, 2025 · Completed: Apr 15, 2026
NCT06818708Collaborator
Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery
NACompleted
20 participants
Started: Mar 20, 2025 · Completed: Jun 26, 2025
NCT06199531Lead Sponsor
Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency
PHASE1/PHASE2Recruiting
6 participants
Started: Feb 13, 2024 · Completed: Jan 31, 2028
Locations (1)
Headquarters
Menlo Park, CA, United States
Map
Loading map...